Fig. 6. Testing of model predictions.

(A) Mass cytometry analysis of CD45 and CD107a in CD56^bright and CD56^dim NK cells (obtained from donor #1) at 256 min after the cells were stimulated with anti-NKG2D antibody having first been treated with medium (NKG2D) or IL-2 (IL-2 + NKG2D). As predicted by the model, IL-2–treated CD56^bright NK cells with greater amounts of CD45 exhibited increased relocalization of CD107a to the cell surface. IL-2–treated CD56^dim NK cells with the greater amounts of CD45 showed a bimodal distribution of CD107a abundances on the cell surface. The dashed red line denotes the correlation between the abundances of CD45 and CD107a. Data are from a single donor and are representative of five independent donors. (B) Mass cytometry analysis of CD11c and CD107a abundances (NK cells obtained from donor #1) at 256 min after IL-2–pretreated CD56^bright and CD56^dim NK cells were stimulated with anti-NKG2D antibody. As predicted by the model, CD11c abundance played no role in determining the extent of NKG2D-stimulated CD107a relocalization in either NK cell subset. Data are from a single donor and are representative of five independent donors. (C) Mass cytometry analysis of the distribution of pErk in CD56^bright and CD56^dim NK cells at 16 min after incubation with medium, PMA alone, or PMA and ionomycin. The NK cells were first pretreated with either IL-2 (orange) or medium (blue). Unstimulated control samples are shown in green. Data are from a single donor and are representative of three independent donors.